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C olorectal cancer (CRC) is the third-most common cancer worldwide. 1 The incidence of CRC has increased by 2-fold in Hong Kong over the past 2 decades. It is the second-most common cancer, and the second-most common cause of cancer death in Hong Kong. It has been estimated that 1 in 23 (4.3%) men in Hong Kong will develop CRC in his lifetime. 2 The majority of cases of CRC are sporadic, 20% are associated with familial clustering, 3 and approximately 6% are accounted for by hereditary nonpolyposis colorectal cancer (HNPCC) and familial adenomatous polyposis syndrome. 4 -6 Meta-analyses and cohort studies have shown that firstdegree relatives (FDRs) of patients with CRC have a 2-fold increased risk of developing CRC compared with the general population. 7, 8 The frequency of a positive self-report colorectal cancer family history is also higher in patients with colonic adenomas. 9 -12 Based on these studies, guidelines recommend screening of close relatives of patients with CRC at an earlier age and more frequently. [13] [14] [15] What remain less clear are the expected findings on colonoscopy in close relatives when the index case has CRC. Data from well-conducted prospective studies are lacking. In an appropriate study design, FDRs of patients with CRC should be compared with FDRs of individuals with negative findings on colonoscopy. Colonoscopy in both groups should be performed during the same time period. In 2003, we conducted a screening colonoscopy study in asymptomatic Chinese patients in Hong Kong. 16 FDRs to individuals with negative colonoscopies from this cohort represented an ideal control group for our current study. We hypothesized that patients with a sibling diagnosed with CRC have an increased risk of advanced neoplasms compared with those without such family history. The objective of this study was to assess the prevalence of advanced neoplasms in siblings of patients with CRC compared with siblings of subjects with normal colonoscopy. These data could provide the basis for planning family-specific screening approaches that could extend the benefits of colonoscopic polypectomy.
Patients and Methods
In this prospective cross-sectional study, we determined the prevalence of colorectal advanced neoplasms in siblings of patients with CRC compared with siblings of subjects without CRC (matched controls). The primary outcome was the prevalence of advanced neoplasms, defined as cancers or adenomas that were at least 10 mm in diameter, had high-grade dysplasia, or had villous or tubulovillous histologic characteristics, or any combination thereof. Secondary outcomes included the rates of all colorectal adenomas, and the prevalence of advanced neoplasms based on the characteristics of the index case.
Siblings of patients with CRC were derived from 2 sources. They were siblings of patients with histologically proven CRC, aged between 40 and 70 years old. Patients with CRC were identified from the Prince of Wales Hospital Colorectal Cancer Surgery Registry between 2001 and 2011. This registry contains data on disease stage, surgical procedure, and survival data of patients who have undergone surgery for CRC at our hospital. Consecutive subjects with CRC were identified from the database and their siblings were contacted. The second source of cases was families with one member with CRC who volunteered to participate in a screening colonoscopy. Family and personal history of CRC was obtained and confirmed by surgical, pathology, and hospital reports (in Ͼ90% of cases). Letters were sent to siblings of patients with CRC to invite them to attend an interview and to undergo a colonoscopy. The letter provided information on the purpose of the study, lifetime risk of developing CRC among FDRs of patients with CRC, adenoma-carcinoma sequence, and complications of colonoscopy. Eight weeks later, reminder letters were sent to those who had not responded. In the absence of a response after a further 8 weeks, family members were contacted by telephone by a research nurse. Siblings with a history of hereditary CRC (HNPCC based on the Amsterdam II criteria, 17 familial adenomatous polyposis, Peutz-Jegher syndrome, juvenile polyposis), inflammatory bowel disease, known colonic adenomas, previous colonic surgery, colonoscopy within the past 5 years, severe cardiopulmonary disease or other comorbidities, and contraindications to colonoscopy, were excluded. All siblings recruited were asymptomatic.
Controls were siblings of asymptomatic subjects who had undergone colonoscopy in our screening program (between 2003 and 2011) and were found to have a normal colonoscopy. 16, 18 The siblings of consecutive subjects with normal colonoscopy were identified from our colonoscopy database and invitation letters were sent to them to attend a health talk on CRC and to have a screening colonoscopy. Interested siblings were interviewed by research nurses to obtain detailed medical and family history. Controls should have no family history of CRC, personal history of hereditary CRC or inflammatory bowel disease, known colonic adenomas or cancer, previous colonic surgery, colonoscopy within the past 5 years, severe cardiopulmonary disease or other comorbidities, or contraindications to colonoscopy. Each sibling of a patient was matched with one sex-and age-matched (Ϯ3 y) control. Controls were matched to siblings of patients before colonoscopy. The study protocol was approved by the Clinical Research Ethics Committee of the Chinese University of Hong Kong and New Territories East Cluster of Hospital Authority of Hong Kong. All study subjects provided informed written consent for participation (Clinical trial number: NCT00164944). All authors had access to the study data and reviewed and approved the final manuscript.
Colonoscopy
Screening colonoscopies using a conventional white-light colonoscope (without high definition) were performed at the Endoscopy Centre at the Prince of Wales Hospital or The Alice Ho Miu-ling Nethersole Hospital by 3 experienced endoscopists (J.Y.W.L., W.-K.L., and S.C.N., who performed 30%, 30%, and 40% of the colonoscopies, respectively). Procedures were performed under conscious sedation with intravenous midazolam and pethidine. A complete examination was defined as the endoscope reaching the cecum, as evidenced by the ileocecal valve or appendiceal orifices. The cecal intubation rate was 100%. The size, location, and morphology of all colonic lesions were documented. Size of lesions was measured with an open biopsy forceps and the location was determined on scope withdrawal. Lesions found proximal to the splenic flexure during scope withdrawal were referred to as proximal lesions. All lesions were removed endoscopically and lesions not amenable to endoscopic removal underwent a biopsy. Endoscopists and the pathologist were blinded to the family history of CRC in study subjects. Endoscopists were informed that the subject was asymptomatic and undergoing a screening colonoscopy but they did not have any information on the family history of CRC or whether it was a study case.
Histology
Colonic lesions were fixed in 10% buffered formalin and embedded in paraffin and sent to a single pathologist (K.-F.T.). The adenoma was classified according to the World Health Organization recommendation. 19 Advanced neoplasm was defined as cancer or adenoma that was at least 10 mm in diameter, had high-grade dysplasia, or had villous or tubulovillous histologic characteristics, or any combination thereof. Large adenomas were defined as adenomas 10 mm or larger in size. Multiple adenomas were defined as more than 3 adenomas. In subjects with multiple adenomas, the most advanced adenoma was considered.
Sample Size Calculation
Sample size calculations were based on the rate of advanced neoplasm. Screening colonoscopy studies in asymptomatic subjects in Asia and the West showed that advanced neoplasm was detected in approximately 5% of asymptomatic subjects. 16,20 -22 We aimed to detect a 2-fold increased risk of advanced neoplasm in siblings of patients with CRC. Assuming an 80% power and 5% type I error rate, a minimum of 374 subjects were required in each group. Sample size was calculated using the StatsDirect statistical package (version 2.7.7; StatsDirect Ltd, Cheshire, United Kingdom).
Statistical Analysis
Data were presented as the mean, standard deviation, or frequency (%). Univariable analysis was conducted by computing matched odds ratios (mORs) and their 95% confidence intervals (CIs) to compare siblings of patients and matched controls for each variable through conditional logistic regression. For multivariable analyses, baseline factors that showed an association with a P value less than .1 in unadjusted analyses were entered into a regression model. In these analyses, the most severe colonoscopic finding was represented as an independent variable in a number of ways. 19 It was considered as a binary variable (all adenomas vs no adenomas), or a 3-level categoric variable (advanced neoplasm vs nonadvanced neoplasm vs no adenomas). To compensate for the familial cluster effect, a subanalysis was performed by including all siblings from families with a single member and one randomly selected sibling from each family with 2 or more members. Finally, stratified conditional logistic regression analyses were performed according to the age of siblings of patients and the characteristics of the index case at diagnosis. Significance was defined by a 2-sided ␣ level of .05. P values were not adjusted for multiple subgroup analyses. All statistical analyses were performed using SPSS software (version 15.0; SPSS, Chicago, IL).
Results
Between 2001 and 2011 there were 374 siblings from 237 families with CRC, and 374 age-and sex-matched controls from 268 families consented to a colonoscopy ( Figure 1A and B). The screening uptake rate in siblings of patients was 63% (374 of 598; in siblings who had a colonoscopy, 374; in siblings who declined participation or failed to attend for colonoscopy, 224; Figure 1 ), and in controls was 49% (374 of 758; in controls eligible to participate, 374; in controls who declined participation or failed to attend for colonoscopy, 384). None of the deceased siblings were diagnosed with CRC.
Aspirin use was less prevalent in siblings of patients than in controls. Other baseline characteristics were comparable between both groups (Table 1) .
Bowel preparation was good in 258 (69%) and 249 (67%), fair in 91 (24%) and 95 (25%), and poor in 25 (7%) and 30 (8%) siblings of patients and controls, respectively. The quality of bowel preparation did not differ between both groups (McNemar test, P ϭ .846). The 3 endoscopists performed a comparable number of procedures in siblings of patients and controls (S.C.N., J.Y.W.L., and W.-K.L., who performed colonoscopies in 37% and 36%, 29% and 33%, and 34% and 31% of siblings of patients and controls, respectively; chi square test; P ϭ .439). Adenoma detection rates were comparable between the endoscopists (S.C.N., 26.0%; J.L., 28.1%; W.-K.L., 22.4%; P ϭ .305).
Prevalence of Advanced Neoplasms
The prevalence of advanced neoplasms was higher in siblings of patients with CRC than in controls (7.5% vs 2.9%; mOR, 3.07; 95% CI, 1.5-6.3; P ϭ .002). Siblings of patients also had a higher prevalence of adenomas that were 10 mm or larger (5.9% vs 2.1%), and all colorectal adenomas (31% vs 18.2%), than controls (Table 2) . Six adenocarcinomas were identified in siblings of patients, but none in controls (Table 2) . Cancers were located in the ascending colon (n ϭ 2), descending colon (n ϭ 1), sigmoid colon (n ϭ 1), and rectum (n ϭ 2).
Two siblings of patients had both cancers and adenomas 10 mm or greater. Two patients had stage 1 cancers, 2 patients had stage 2 cancers, and the remaining 2 patients had stage 3 cancers. Small adenomas were present in 24.3% of siblings of patients and in 15.2% of controls (mOR, 2.03; 95% CI, 1.37-3.00; P Ͻ .001). There were more adenomas in men than in women in siblings of patients (36.9% vs 27.1%) and controls (20.8% vs 16.4%). There were more distal adenomas (13.1% vs 8.3%; P ϭ .006), proximal adenomas (12.0% vs 6.2%; P ϭ .007), and synchronous adenomas (5.9% vs 2.7%; P ϭ .004) in siblings of patients than in controls ( Table 2 ). The prevalence of hyperplastic polyps was similar between siblings of patients and controls (27.3% vs 21.4%; P ϭ .564).
In siblings of patients, there were 18 (4.8%) and 8 (2.1%) advanced neoplasms in the distal and proximal colon, respectively, and 2 (0.53%) synchronous advanced adenomas. In controls, there were 5 (1.3%) advanced neoplasms in both the distal and proximal colon, and 1 synchronous advanced adenoma (0.27%). In the 2 subjects with proximal CRC (ascending colon), both (100%) had distal adenomas. In the 8 subjects with advanced adenomas in the proximal colon, 2 (25%) subjects had distal adenomas.
Restriction of analysis to siblings of patients and controls composed of only 1 sibling per family (n ϭ 172) did not affect the risk estimates for advanced neoplasms (OR, 3.08; 95% CI, 1.16 -8.15; P ϭ .024) or overall colorectal adenomas (OR, 2.37; 95% CI, 1.37-4.09; P ϭ .002).
Siblings of patients were more likely to have distal, proximal, and synchronous adenomas than were controls (Table 2) . After stratification by age, siblings of patients aged younger than 50 years had a higher prevalence of all colorectal adenomas (21.0% vs 9.8%; mOR, 2.67; P ϭ .012) than did controls. The prevalence of advanced neoplasms was also higher in siblings of patients than in controls (3.8% vs 0.8%), although the difference in advanced neoplasms did not reach statistical significance, likely because of the small number of subjects in each subgroup. Siblings of patients aged 50 to 60 years had a higher prevalence of all colorectal adenomas (34.4% vs 23.9%; mOR, 1.82; P ϭ .023) than did controls. In subjects older than 60 years of age, the risk of advanced neoplasms (11.5% vs 2.6%; mOR, 5.53; P ϭ .036) and all colorectal adenomas (41.0% vs 20.5%; mOR, 2.68; P ϭ .012) was higher in siblings of patients than in controls ( Table 3) .
The restriction of the analysis only to siblings of patients in whom an index case CRC was confirmed on pathology (n ϭ 346) showed that the risk for advanced neoplasms (mOR, 2.71; 95% CI, 1.30 -5.64; P ϭ .008) and for all colorectal adenomas (mOR, 2.12; 95% CI, 1.46 -3.10; P Ͻ .001) remained significantly higher in siblings of patients than in controls. Exclusion of analysis in siblings who volunteered to participate (in case they were a highly selected group who may be symptomatic and keen for a colonoscopy; n ϭ 137) showed that the risk of advanced neoplasms (mOR, 2.53; 95% CI, 1.02-6.33; P ϭ .046) and all colorectal adenomas (mOR, 2.12; 95% CI, 1.33-3.37; P ϭ .001) remained increased in siblings of patients compared with controls.
Influence of Index Cancer Patient's Characteristics on Risk of Colorectal Neoplasm
The risk of having advanced neoplasms in siblings was higher when their index case was female (mOR, 4.95; 95% CI, 1.81-13.55) and when the index case was aged 60 years or older (mOR, 3.09; 95% CI, 1.24-7.73). Furthermore, the risk of developing advanced neoplasms (mOR, 3.1; 95% CI, 1.34-7.14) or any colorectal adenomas (mOR, 2.19; 95% CI, 1.45-3.30) was significantly higher in siblings when the index case presented with distal but not proximal CRC (Table 4 ).
Discussion
We found that siblings of Chinese subjects with CRC have a 3-fold increased risk of advanced colorectal neoplasms including cancers, and a 2-fold increased risk of any colorectal adenomas when compared with siblings of subjects with a normal colonoscopy. This risk is higher if the index case had a CRC in the distal colon.
These data are consistent with 2 earlier studies. 11, 23 In an Italian prospective cohort study, asymptomatic patients who had one FDR with CRC had a 2-fold increased risk of adenomas with more proximal and severely dysplastic lesions compared with the control population. 11 A case-control study from France showed that the prevalence of "high risk" adenomas was significantly higher in FDRs of patients with sporadic CRC compared with controls who underwent a colonoscopy during the same period. 23 Our findings have confirmed that close relatives of subjects with CRC are not only at an increased risk of CRC but they also have a higher risk of advanced adenomas. CRC screening with the removal of these premalignant lesions is currently the most effective way to reduce cancer incidence and cancer death, 24 -27 and is strongly indicated in this high-risk group.
Our study had a unique design. It offered colonoscopy to siblings of adenoma-and cancer-free patients. These siblings were asymptomatic and had been matched closely to siblings of cancer patients. The use of such a control group avoids a biased estimate of the association with family history, and removes the acquired or environmental component to this association. 12 Earlier studies mostly have included consecutive patients who had undergone colonoscopy as controls 11, 23 ; some of these controls had presented with bowel symptoms and may not represent a satisfactory control population. Furthermore, the findings in control subjects were fully validated using a colonoscopy. Siblings to subjects with a normal colonoscopy represent a group more comparable with case subjects and a better control group. Therefore, the advanced neoplasm rates in controls in our study were lower compared with other case-control studies. 23, 28 Second, the evidence for screening in FDRs of patients with CRC has been derived mostly from Western studies. We have provided data from the Asian population, confirming that this high-risk population deserves screening. 20 The risk of advanced neoplasm appeared higher when the index case had CRC located in the distal colon, 28 and was confirmed in our study.
Families with HNPCC syndrome usually have lesions present in the proximal colon and they were excluded in this study. In this study, which focused on nonpolyposis CRC, the risk of left-sided, or distal advanced neoplasm risk, also is increased in the siblings of these patients.
Consistent with work from others, we have found that advanced neoplasms and colorectal adenomas were more prevalent in men than in women. 29, 30 Although we found that having an index case with CRC who is female put their siblings at a greater risk of advanced neoplasms, this observation will need to be confirmed in larger series because the number of subjects in each subgroup was small.
This study had several clinical implications. Until recently, no local data were available to help in more targeted screening in our population. 16 Several countries in Asia have reported an increase in the incidence of CRC. 31 Information obtained from this study can help establish the risk to FDRs of affected individuals, and provide a background against which screening strategies can be formulated. Second, current recommendations for screening in family members with CRC are based largely on calculations of lifetime risk for CRC in relatives instead of on reported outcomes. In this prospective study, we showed our findings detected on colonoscopy of close relatives of a proband with CRC. The higher prevalence of advanced neoplasms detected on colonoscopy further contributes to the current literature and anchors the guideline recommendations for screening. Although our study used colonoscopy as the screening tool, the 2 proximal CRCs found in siblings of patients with CRC were associated with distal adenomas and may have been detected with sigmoidoscopy or fecal immunochemical testing.
Our study results also should be interpreted in light of several limitations. First, because we did not test all siblings or FDRs we cannot confirm that all siblings of patients with CRC or control families were polyp-or cancer-free. Not all individuals in one family may agree to have a colonoscopy. Theoretically, such incompleteness should have a nondifferential effect, and we expect that it would affect both groups to a similar extent. Second, a small minority of CRCs (Ͻ10%) in the index subject was not confirmed histologically, and history from cases may be subjected to recall bias. Nonetheless, after exclusion of these subjects, the prevalence of advanced neoplasms remains significantly higher in siblings of patients than controls. Third, we did not include familial clustering in sample size calculations because a substantially larger sample size would be required. To reduce the effects of familial clustering, a subanalysis was performed limited to one random case from each family, which did not affect the risk estimates for advanced neoplasms and cancers. Fourth, siblings of patients and control siblings were not drawn from the same population, which could lead to selection bias. Cases who volunteered to participate may represent a highly self-selected group because of concern of symptoms, but even when we excluded this group who volunteered, the risk of advanced neoplasms remained significantly higher in siblings of patients than controls. Ideally, subjects who were used to identify the siblings (index case and colonoscopy-negative subject) should be matched for age. After exclusion of matched siblings whose index cases ages were 3 to 5 years older than controls, we found that the odds ratio for advanced neoplasms remained significantly higher in siblings of patients than in controls. Finally, other risk factors for CRC such as physical inactivity or dietary factors were not recorded.
In conclusion, we observed a strong and significant increased risk of advanced neoplasms including cancers in close relatives of subjects with CRC. Siblings of individuals with CRC deserve screening.
